<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Microinvasive breast carcinoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Microinvasive breast carcinoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Microinvasive breast carcinoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Laura C Collins, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christine Laronga, MD, FACS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Julia S Wong, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lori J Pierce, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anees B Chagpar, MD, MSc, MA, MPH, MBA, FACS, FRCS(C)</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel F Hayes, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H564859980"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Microinvasive breast carcinoma is defined as invasive carcinoma of the breast with no invasive focus measuring more than 1 mm [<a href="#rid1">1</a>]. It is most commonly encountered in the setting of ductal carcinoma in situ (DCIS); thus, it is usually referred to as DCIS with microinvasion. It is less frequently seen in association with lobular carcinoma in situ (LCIS) or in the absence of carcinoma in situ.</p><p>The epidemiology, clinical presentation, pathology, and treatment of microinvasive breast carcinoma will be reviewed here. DCIS and LCIS are presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14220.html" rel="external">"Ductal carcinoma in situ: Treatment and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14219.html" rel="external">"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/743.html" rel="external">"Atypia and lobular carcinoma in situ: High-risk lesions of the breast"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/783.html" rel="external">"Pathology of breast cancer"</a>.)</p><p></p><p class="headingAnchor" id="H564859987"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Data about the epidemiology and clinical significance of microinvasive breast carcinoma have been limited by its uncommon incidence and the historical lack of a standardized definition.</p><p class="headingAnchor" id="H564859994"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>The incidence of microinvasive breast carcinoma appears to have increased in parallel with the rising incidence of ductal carcinoma in situ (DCIS), which has been attributed primarily to the introduction of breast cancer screening programs as well as more thorough sampling of breast tissue specimens.</p><p>Nevertheless, pure microinvasive breast carcinoma (without associated DCIS) remains an uncommon disease, estimated as accounting for less than 1 percent of all breast cancers [<a href="#rid2">2,3</a>]. As with invasive breast cancer, microinvasive breast carcinoma is predominantly ductal in histologic type.</p><p>Risk factors for microinvasive breast carcinoma appear to be similar to those associated with DCIS, such as nulliparity and family history of breast cancer [<a href="#rid2">2,3</a>]. It occurs over a wide age range (30 to 85 years of age), with the average age in the 50 to 60s [<a href="#rid3">3,4</a>]. Case series have also suggested that patients diagnosed with microinvasive breast carcinoma have a high incidence of other high-risk lesions, including concurrent breast carcinoma and other malignancies, present at the time of diagnosis [<a href="#rid2">2,3</a>].</p><p>The epidemiology of DCIS is presented separately. (See  <a class="medical medical_review" href="/d/html/14219.html" rel="external">"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H564860001"><span class="h2">Definition, pathology, and staging</span><span class="headingEndMark"> — </span>Microinvasive breast carcinoma is defined by the American Joint Committee on Cancer and the International Union for Cancer Control (AJCC-UICC) as invasive carcinoma of the breast with no focus measuring more than 1 mm [<a href="#rid5">5</a>]. It is most commonly encountered in the setting of DCIS, where small foci of tumor cells have invaded through the basement membrane into the surrounding stroma. It is rarely seen in association with lobular carcinoma in situ (LCIS) or in the absence of carcinoma in situ [<a href="#rid4">4</a>]. Where associated with LCIS, the microinvasive component is usually lobular or occasionally tubular in histologic type.</p><p>According to the eighth edition Tumor, Node, Metastasis staging system as well as the preceding seventh edition, microinvasive breast carcinoma is designated as T1mi, as presented in the respective tables  (<a class="graphic graphic_table graphicRef110848" href="/d/graphic/110848.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef65393" href="/d/graphic/65393.html" rel="external">table 2</a>). In cases with multiple foci of microinvasion (where no focus is larger than 1 mm), the number of foci and range of sizes should be reported. Note that the sizes of individual foci of microinvasion are not added together. Since microinvasive breast carcinoma may present with multiple foci of invasion, the pathologic specimen should be carefully examined for additional foci [<a href="#rid6">6,7</a>].</p><p>Histopathologically, microinvasive breast carcinoma tends to be associated with high-grade DCIS and comedo-type necrosis [<a href="#rid2">2,8-10</a>]. There is also evidence that the risk of microinvasion increases with larger-size DCIS lesions and multicentric DCIS [<a href="#rid8">8-10</a>]. (See  <a class="medical medical_review" href="/d/html/783.html" rel="external">"Pathology of breast cancer"</a>.)</p><p>There is little information about biologic markers such as estrogen receptor (ER) and progesterone receptor (PR) status and human epidermal growth factor receptor 2 (HER2) overexpression in microinvasive breast carcinoma [<a href="#rid2">2,11,12</a>]. In a study including 30 patients who had complete hormone receptor testing of both the invasive and in situ components, ER/PR positivity was 100 percent concordant in both microinvasive and in situ disease; ER negativity was 83 percent concordant. HER2 status was 100 percent concordant [<a href="#rid13">13</a>]. Contrary to invasive breast cancer, the limited data suggest that receptor expression has little prognostic significance in microinvasive breast cancer. (See <a class="local">'Prognosis'</a> below.)</p><p class="headingAnchor" id="H564860008"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>Microinvasive breast carcinoma commonly presents within a palpable mass that represents an area of DCIS with stromal desmoplasia [<a href="#rid2">2-4,8,9,14-16</a>]. The microinvasion in and of itself is not palpable. Nipple discharge rarely may also occur.</p><p>Others have found that, similar to DCIS, the most frequent imaging appearance is calcifications [<a href="#rid2">2</a>]. These different results are likely due to differences between studies in the definition of microinvasive breast carcinoma used, which imaging studies were performed (ie, mammography or ultrasonography), and degree of tissue sampling. For example, a retrospective review of 37 patients with microinvasive breast cancer and 44 patients with intraductal carcinoma found that the most dominant magnetic resonance imaging (MRI) finding of both lesions was heterogeneous enhancement of non-mass-like lesions [<a href="#rid17">17</a>].</p><p>Most diagnostic biopsies are performed as core needle biopsies. As such, pathology results may only reveal DCIS or DCIS with a focus "suspicious for" microinvasion. It is only when the entire lesion is removed that a complete evaluation can be performed and a final diagnosis of invasive or microinvasive breast carcinoma can be rendered.</p><p class="headingAnchor" id="H564860015"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H564860022"><span class="h2">Management of the breast</span><span class="headingEndMark"> — </span>There are no randomized trials to inform the optimal surgical treatment for microinvasive breast carcinoma. Breast-conserving surgery (BCS) followed by radiation therapy (RT) for most patients with microinvasive breast carcinoma is appropriate. However, mastectomy (without RT) may be preferred for patients in whom the ductal carcinoma in situ (DCIS) component is large, high grade, with or without comedo necrosis <strong>and</strong> in whom clean margins cannot be definitively obtained with BCS.</p><p>BCS may be associated with an increased risk of local recurrence; RT after BCS minimizes this risk. For those with pure microinvasive carcinoma, margin requirements are the same as for those with invasive carcinoma (ie, no tumor on ink); however, for microinvasive carcinoma associated with DCIS, the larger margin requirements needed for DCIS are required. (See  <a class="medical medical_review" href="/d/html/739.html" rel="external">"Adjuvant radiation therapy for women with newly diagnosed, non-metastatic breast cancer"</a> and  <a class="medical medical_review" href="/d/html/14220.html" rel="external">"Ductal carcinoma in situ: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/807.html" rel="external">"Breast-conserving therapy"</a> and  <a class="medical medical_review" href="/d/html/14981.html" rel="external">"Mastectomy"</a>.)</p><p>As with DCIS and early invasive breast cancer, BCS for microinvasive breast carcinoma appears to achieve excellent outcomes [<a href="#rid13">13,18</a>]. In a retrospective study of 321 patients with DCIS and 72 patients with microinvasion treated with BCS, the presence of microinvasion did not correlate with local recurrence rate, distant relapse-free survival, or overall survival at almost nine years of follow-up [<a href="#rid18">18</a>]. The improved outcomes in contemporary series may be due at least in part to the use of adjuvant endocrine therapy for patients whose disease is estrogen receptor positive.</p><p>The risk of recurrence following BCS for microinvasive disease appears to be increased with:</p><p class="bulletIndent1"><span class="glyph">●</span>Positive excision margins [<a href="#rid13">13,19</a>] (see <a class="local">'Prognosis'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Size of the DCIS component [<a href="#rid3">3,4</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Unfavorable histopathologic characteristics of the associated DCIS component (ie, presence of comedo necrosis and high nuclear grade) [<a href="#rid9">9</a>]</p><p></p><p>As described above, these characteristics are common with microinvasive breast carcinoma. (See <a class="local">'Overview'</a> above.)</p><p class="headingAnchor" id="H564860029"><span class="h2">Management of the axilla</span><span class="headingEndMark"> — </span>The reported incidence of axillary lymph node involvement in microinvasive breast carcinoma ranges from 0 to 20 percent but is generally 5 percent or less for properly defined microinvasive breast carcinoma [<a href="#rid4">4,8,19-28</a>]. The likelihood of axillary node involvement is greater in cases where stromal invasion is demonstrated by clusters of cells rather than single cells [<a href="#rid6">6,8,14,15</a>].</p><p>Although the majority of patients with microinvasive breast carcinoma are likely to have negative axillary lymph nodes, we proceed with a sentinel lymph node biopsy for patients in whom the assessment of axillary lymph node status will influence adjuvant therapy decisions. Omission of the sentinel lymph node for select older women with hormone-positive disease is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/757.html" rel="external">"Overview of the approach to early breast cancer in older women", section on 'Management of the axilla'</a>.)</p><p>The importance of identifying nodal metastasis in T1mi patients should be further investigated to determine the impact, if any, on local-regional recurrence or distant disease [<a href="#rid27">27,28</a>]. (See  <a class="medical medical_review" href="/d/html/810.html" rel="external">"Overview of sentinel lymph node biopsy in breast cancer"</a> and  <a class="medical medical_review" href="/d/html/810.html" rel="external">"Overview of sentinel lymph node biopsy in breast cancer", section on 'DCIS with suspicious features'</a>.)</p><p class="headingAnchor" id="H2348975351"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Microinvasive breast carcinoma has an excellent prognosis, with a five-year overall survival between 97 and 100 percent [<a href="#rid9">9</a>]. Survival seems to be intermediate between pure ductal carcinoma in situ (DCIS) and small invasive carcinomas [<a href="#rid11">11</a>].</p><p>For women with microinvasive carcinoma, the risk of recurrence following surgery (breast-conserving therapy or mastectomy) appears to be small. In one study of 83 patients followed for a median of six years, the cumulative incidence of recurrence at five years was 5 percent [<a href="#rid13">13</a>]. The postexcision finding of close or positive margins (≤2 mm) on pathologic evaluation was the only factor associated with an increased risk of a local recurrence, which was diagnosed in 4 of 20 patients who had a close margin versus 2 of 62 who had a negative margin (hazard ratio 8.8, 95% CI 1.6-48.8). This small study also reported that overexpression of human epidermal growth factor 2 was not associated with the risk of axillary node involvement at diagnosis or the risk of recurrence.</p><p class="headingAnchor" id="H564860036"><span class="h1">IS THERE A ROLE FOR ADJUVANT SYSTEMIC THERAPY?</span><span class="headingEndMark"> — </span>There have been no clinical trials specifically addressing the role of adjuvant endocrine therapy, chemotherapy, and/or <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> in the treatment of microinvasive breast carcinoma. In the absence of definitive data, we treat microinvasive cancer similarly to ductal carcinoma in situ (DCIS), specifically:</p><p class="bulletIndent1"><span class="glyph">●</span>Adjuvant endocrine therapy is appropriate for most women with hormone receptor (HR)-positive microinvasive breast cancer. In this instance, the role of endocrine therapy is as "chemoprevention" either for the remaining breast tissue or the contralateral side, since the odds of distant recurrence and mortality from the microinvasive carcinoma are so low. The approach to these patients is similar to that for women with DCIS. (See  <a class="medical medical_review" href="/d/html/14220.html" rel="external">"Ductal carcinoma in situ: Treatment and prognosis", section on 'Endocrine therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Given that by definition these patients have a primary breast tumor ≤1 mm, chemotherapy is not administered in the absence of nodal involvement. For patients who have microinvasive disease in the breast who are found concurrently to have metastatic disease in the lymph nodes, decisions regarding chemotherapy depend on receptor status and risk factors of the cancer. (See  <a class="medical medical_review" href="/d/html/126631.html" rel="external">"Deciding when to use adjuvant chemotherapy for hormone receptor-positive, HER2-negative breast cancer"</a> and  <a class="medical medical_review" href="/d/html/14227.html" rel="external">"ER/PR negative, HER2-negative (triple-negative) breast cancer", section on 'Non-metastatic disease'</a> and  <a class="medical medical_review" href="/d/html/773.html" rel="external">"Adjuvant systemic therapy for HER2-positive breast cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The prognostic significance of hormone and/or human epidermal growth factor 2 (HER2) receptor expression is uncertain due to the paucity of available data. Often, there is not enough tissue for hormone and HER2 analysis. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p>The evidence underlying these recommendations for adjuvant therapy for early-stage breast cancer is discussed separately. (See  <a class="medical medical_review" href="/d/html/737.html" rel="external">"Overview of the treatment of newly diagnosed, invasive, non-metastatic breast cancer"</a>.)</p><p class="headingAnchor" id="H1110699486"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/121833.html" rel="external">"Society guideline links: Ductal carcinoma in situ"</a>.)</p><p class="headingAnchor" id="H23375923"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16835.html" rel="external">"Patient education: Ductal carcinoma in situ (DCIS) (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H564860050"><span class="h1">SUMMARY AND RECOMMENDATIONS</span><span class="headingEndMark"> — </span>Microinvasive breast carcinoma is defined as invasive carcinoma of the breast with no focus measuring more than 1 mm; it is invariably encountered in the setting of ductal carcinoma in situ (DCIS).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – The risk of microinvasive breast carcinoma increases with larger-size DCIS lesions and multicentric DCIS. It tends to be associated with high-grade DCIS and DCIS with comedo necrosis and in that setting is more likely to present with multiple foci of microinvasion. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1">According to the eighth edition American Joint Committee on Cancer and the International Union for Cancer Control Tumor, Node, Metastasis staging system, microinvasive breast carcinoma is designated as T1mi. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of the breast</strong> – The optimal treatment for microinvasive breast cancer is undefined. We suggest breast-conserving surgery (BCS) followed by radiation therapy to reduce the risk of local recurrence (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). However, mastectomy may be preferred for patients at high risk of local recurrence with breast-conserving therapy, including those with extensive, multicentric, high-grade DCIS, with or without comedo necrosis and for those patients when histologically clear margins cannot be obtained with BCS. (See <a class="local">'Management of the breast'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of the axilla</strong> – We proceed with sentinel lymph node biopsy (SLNB) for patients with confirmed microinvasive breast carcinoma in whom the assessment of axillary lymph node status will influence adjuvant therapy decisions (see <a class="local">'Management of the axilla'</a> above). Omission of SLNB for older women with hormone receptor-positive breast cancer is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/757.html" rel="external">"Overview of the approach to early breast cancer in older women", section on 'Management of the axilla'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Microinvasive breast carcinoma has an excellent prognosis, with a greater than 95 percent five-year overall survival. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjuvant systemic therapy</strong> – Adjuvant endocrine therapy is appropriate for most women with hormone receptor (HR)-positive microinvasive breast cancer. In this instance, the role of endocrine therapy is as "chemoprevention" either for the remaining breast tissue or the contralateral side, since the odds of distant recurrence and mortality from microinvasive carcinoma are so low. The approach to these patients is similar to that for women in invasive HR-positive breast cancer. (See  <a class="medical medical_review" href="/d/html/749.html" rel="external">"Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer"</a>.)</p><p></p><p class="bulletIndent1">Given that by definition these patients have a primary breast tumor ≤1 mm, chemotherapy is not administered in the absence of nodal involvement. For patients who have microinvasive disease in the breast who are found concurrently to have macrometastatic disease to the lymph nodes, decisions regarding chemotherapy depend on receptor status and risk factors of the cancer. (See  <a class="medical medical_review" href="/d/html/788.html" rel="external">"Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer"</a> and  <a class="medical medical_review" href="/d/html/773.html" rel="external">"Adjuvant systemic therapy for HER2-positive breast cancer"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">(American Joint Committee on Cancer) Cancer Staging Manual, 7th ed, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.</li><li><a class="nounderline abstract_t">Vieira CC, Mercado CL, Cangiarella JF, et al. Microinvasive ductal carcinoma in situ: clinical presentation, imaging features, pathologic findings, and outcome. Eur J Radiol 2010; 73:102.</a></li><li><a class="nounderline abstract_t">Padmore RF, Fowble B, Hoffman J, et al. Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience. Cancer 2000; 88:1403.</a></li><li class="breakAll">Silverstein MJ, Lagios MD. Ductal carcinoma in situ with microinvasion. In: Ductal Carcinoma in Situ of the Breast, Silverstein MJ (Ed), Lippincott Williams and Wilkins, Philadelphia 2002. p.523.</li><li class="breakAll">AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 8th ed, third printing, Amin MB, Edge SB, Greene FL, et al (Eds), Springer, Chicago 2018.</li><li><a class="nounderline abstract_t">Si J, Guo R, Pan H, et al. Multiple Microinvasion Foci in Ductal Carcinoma In Situ Is Associated With an Increased Risk of Recurrence and Worse Survival Outcome. Front Oncol 2020; 10:607502.</a></li><li><a class="nounderline abstract_t">Major-Stević M, Cajkas I, Hegedis-Bercek I, et al. [Results in the treatment of Guillain-Barre syndrome with corticosteroids]. Med Pregl 1988; 41:487.</a></li><li><a class="nounderline abstract_t">de Mascarel I, MacGrogan G, Mathoulin-Pélissier S, et al. Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas. Cancer 2002; 94:2134.</a></li><li><a class="nounderline abstract_t">Adamovich TL, Simmons RM. Ductal carcinoma in situ with microinvasion. Am J Surg 2003; 186:112.</a></li><li><a class="nounderline abstract_t">Sue GR, Lannin DR, Killelea B, Chagpar AB. Predictors of microinvasion and its prognostic role in ductal carcinoma in situ. Am J Surg 2013; 206:478.</a></li><li><a class="nounderline abstract_t">Strang LR, Sun J, Sun W, et al. Characteristics of Microinvasive Ductal Carcinoma In Situ Versus Noninvasive and Invasive Breast Cancer. J Surg Res 2020; 254:378.</a></li><li><a class="nounderline abstract_t">Liu BT, Ding JN, Wang JL, et al. Differences in pathologic characteristics between ductal carcinoma in situ (DCIS), DCIS with microinvasion and DCIS with invasive ductal carcinoma. Int J Clin Exp Pathol 2020; 13:1066.</a></li><li><a class="nounderline abstract_t">Margalit DN, Sreedhara M, Chen YH, et al. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy. Ann Surg Oncol 2013; 20:811.</a></li><li><a class="nounderline abstract_t">Sopik V, Sun P, Narod SA. Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ. Breast Cancer Res Treat 2018; 167:787.</a></li><li><a class="nounderline abstract_t">Kim M, Kim HJ, Chung YR, et al. Microinvasive Carcinoma versus Ductal Carcinoma In Situ: A Comparison of Clinicopathological Features and Clinical Outcomes. J Breast Cancer 2018; 21:197.</a></li><li><a class="nounderline abstract_t">Champion CD, Ren Y, Thomas SM, et al. DCIS with Microinvasion: Is It In Situ or Invasive Disease? Ann Surg Oncol 2019; 26:3124.</a></li><li><a class="nounderline abstract_t">Hahn SY, Han BK, Ko EY, et al. MR features to suggest microinvasive ductal carcinoma of the breast: can it be differentiated from pure DCIS? Acta Radiol 2013; 54:742.</a></li><li><a class="nounderline abstract_t">Parikh RR, Haffty BG, Lannin D, Moran MS. Ductal carcinoma in situ with microinvasion: prognostic implications, long-term outcomes, and role of axillary evaluation. Int J Radiat Oncol Biol Phys 2012; 82:7.</a></li><li><a class="nounderline abstract_t">Solin LJ, Fowble BL, Yeh IT, et al. Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation. Int J Radiat Oncol Biol Phys 1992; 23:961.</a></li><li><a class="nounderline abstract_t">Silver SA, Tavassoli FA. Mammary ductal carcinoma in situ with microinvasion. Cancer 1998; 82:2382.</a></li><li><a class="nounderline abstract_t">Wong JH, Kopald KH, Morton DL. The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. Arch Surg 1990; 125:1298.</a></li><li><a class="nounderline abstract_t">Prasad ML, Osborne MP, Giri DD, Hoda SA. Microinvasive carcinoma (T1mic) of the breast: clinicopathologic profile of 21 cases. Am J Surg Pathol 2000; 24:422.</a></li><li><a class="nounderline abstract_t">Wong SL, Chao C, Edwards MJ, et al. Frequency of sentinel lymph node metastases in patients with favorable breast cancer histologic subtypes. Am J Surg 2002; 184:492.</a></li><li><a class="nounderline abstract_t">Klauber-DeMore N, Tan LK, Liberman L, et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol 2000; 7:636.</a></li><li><a class="nounderline abstract_t">Zavagno G, Belardinelli V, Marconato R, et al. Sentinel lymph node metastasis from mammary ductal carcinoma in situ with microinvasion. Breast 2007; 16:146.</a></li><li><a class="nounderline abstract_t">Pimiento JM, Lee MC, Esposito NN, et al. Role of axillary staging in women diagnosed with ductal carcinoma in situ with microinvasion. J Oncol Pract 2011; 7:309.</a></li><li><a class="nounderline abstract_t">Kapoor NS, Shamonki J, Sim MS, et al. Impact of multifocality and lymph node metastasis on the prognosis and management of microinvasive breast cancer. Ann Surg Oncol 2013; 20:2576.</a></li><li><a class="nounderline abstract_t">Lyons JM 3rd, Stempel M, Van Zee KJ, Cody HS 3rd. Axillary node staging for microinvasive breast cancer: is it justified? Ann Surg Oncol 2012; 19:3416.</a></li></ol></div><div id="topicVersionRevision">Topic 14221 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : (American Joint Committee on Cancer) Cancer Staging Manual, 7th ed, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19026501" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Microinvasive ductal carcinoma in situ: clinical presentation, imaging features, pathologic findings, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10717623" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10717623" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10717623" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33344258" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Multiple Microinvasion Foci in Ductal Carcinoma In Situ Is Associated With an Increased Risk of Recurrence and Worse Survival Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3253526" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : [Results in the treatment of Guillain-Barre syndrome with corticosteroids].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12001109" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12885600" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Ductal carcinoma in situ with microinvasion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23791403" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Predictors of microinvasion and its prognostic role in ductal carcinoma in situ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32535256" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Characteristics of Microinvasive Ductal Carcinoma In Situ Versus Noninvasive and Invasive Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32509080" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Differences in pathologic characteristics between ductal carcinoma in situ (DCIS), DCIS with microinvasion and DCIS with invasive ductal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22956068" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29119353" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29963116" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Microinvasive Carcinoma versus Ductal Carcinoma In Situ: A Comparison of Clinicopathological Features and Clinical Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31342393" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : DCIS with Microinvasion: Is It In Situ or Invasive Disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23588154" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : MR features to suggest microinvasive ductal carcinoma of the breast: can it be differentiated from pure DCIS?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20950955" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Ductal carcinoma in situ with microinvasion: prognostic implications, long-term outcomes, and role of axillary evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1322388" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9635531" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mammary ductal carcinoma in situ with microinvasion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2171453" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10716157" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Microinvasive carcinoma (T1mic) of the breast: clinicopathologic profile of 21 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12488144" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Frequency of sentinel lymph node metastases in patients with favorable breast cancer histologic subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11034239" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17046258" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Sentinel lymph node metastasis from mammary ductal carcinoma in situ with microinvasion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22211128" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Role of axillary staging in women diagnosed with ductal carcinoma in situ with microinvasion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23468047" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Impact of multifocality and lymph node metastasis on the prognosis and management of microinvasive breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22576061" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Axillary node staging for microinvasive breast cancer: is it justified?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
